drugset / Trial / NCT04398134
A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection
RandomizedParallel-groupDouble-blindTreatment
Summary
This Phase 2a study will assess the safety, antiviral activity, and pharmacokinetics (PK) of ABI-H2158 administered once daily for up to 72 weeks in combination with entecavir (ETV) in participants with chronic hepatitis B virus (HBV) infection.
Timeline
- Start
- 2020-08-28
- Primary completion
- 2021-10-14
- Completion
- 2021-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABI-H2158 | Unknown | 300 mg | Oral |
| Background | Entecavir | Small molecule | 0.5 mg | Oral |